昊帆生物：公司经营正常，核心业务稳步推进

Group 1 - The company, Haofan Bio (301393), stated that its operations are normal and its core business is steadily advancing [1] - The company is continuously improving operational efficiency and core competitiveness [1] - The company aims to reward investors with good operating performance [1] Group 2 - The stock price is influenced by multiple factors in the secondary market, and investors are advised to view it rationally [1]